Limits...
Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss.

Li X, Liu Y, Zhang R, Tan J, Chen L, Liu Y - Med. Sci. Monit. (2015)

Bottom Line: We found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34-2.67; P=0.0003).However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84-2.59; P=0.18).In conclusion, this meta-analysis suggests that PAI-1 4G/5G polymorphism might be associated with RPL development in Caucasians.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland).

ABSTRACT

Background: The association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and recurrent pregnancy loss (RPL) risk is still contradictory. We thus performed a meta-analysis.

Material and methods: Relevant studies were searched for in PubMed, Web of Science, Embase, and Cochrane Library. An odds ratio (OR) with a 95% confidence interval (CI) was used to assess the association between PAI-1 4G/5G polymorphism and RPL risk.

Results: A total of 22 studies with 4306 cases and 3076 controls were included in this meta-analysis. We found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34-2.67; P=0.0003). In the subgroup analysis by race, PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk in Caucasians (OR=2.23; 95% CI 1.44-3.46; P=0.0003). However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84-2.59; P=0.18).

Conclusions: In conclusion, this meta-analysis suggests that PAI-1 4G/5G polymorphism might be associated with RPL development in Caucasians.

Show MeSH

Related in: MedlinePlus

Forest plot of RPL risk associated with PAI-1 4G/5G polymorphism.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4403499&req=5

f1-medscimonit-21-1051: Forest plot of RPL risk associated with PAI-1 4G/5G polymorphism.

Mentions: As shown in Figure 1, we found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34–2.67; P=0.0003). In the subgroup analysis by race, PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk in Caucasians (OR=2.23; 95% CI 1.44–3.46; P=0.0003). However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84–2.59; P=0.18). Results of the meta-analysis are listed in Table 2. In the sensitivity analysis, when the fixed-effects model was used, the result was still positive (OR=1.87; 95% CI 1.64–2.13; P<0.00001). When the studies without HWE were excluded, the result was not changed (OR=1.56; 95% CI 1.12–2.19; P=0.009). Furthermore, when the studies with small sample size were excluded, the result was also not changed (OR=1.98; 95% CI 1.25–3.13; P=0.004). The results of sensitivity analysis are listed in Table 3.


Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss.

Li X, Liu Y, Zhang R, Tan J, Chen L, Liu Y - Med. Sci. Monit. (2015)

Forest plot of RPL risk associated with PAI-1 4G/5G polymorphism.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4403499&req=5

f1-medscimonit-21-1051: Forest plot of RPL risk associated with PAI-1 4G/5G polymorphism.
Mentions: As shown in Figure 1, we found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34–2.67; P=0.0003). In the subgroup analysis by race, PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk in Caucasians (OR=2.23; 95% CI 1.44–3.46; P=0.0003). However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84–2.59; P=0.18). Results of the meta-analysis are listed in Table 2. In the sensitivity analysis, when the fixed-effects model was used, the result was still positive (OR=1.87; 95% CI 1.64–2.13; P<0.00001). When the studies without HWE were excluded, the result was not changed (OR=1.56; 95% CI 1.12–2.19; P=0.009). Furthermore, when the studies with small sample size were excluded, the result was also not changed (OR=1.98; 95% CI 1.25–3.13; P=0.004). The results of sensitivity analysis are listed in Table 3.

Bottom Line: We found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34-2.67; P=0.0003).However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84-2.59; P=0.18).In conclusion, this meta-analysis suggests that PAI-1 4G/5G polymorphism might be associated with RPL development in Caucasians.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland).

ABSTRACT

Background: The association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and recurrent pregnancy loss (RPL) risk is still contradictory. We thus performed a meta-analysis.

Material and methods: Relevant studies were searched for in PubMed, Web of Science, Embase, and Cochrane Library. An odds ratio (OR) with a 95% confidence interval (CI) was used to assess the association between PAI-1 4G/5G polymorphism and RPL risk.

Results: A total of 22 studies with 4306 cases and 3076 controls were included in this meta-analysis. We found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34-2.67; P=0.0003). In the subgroup analysis by race, PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk in Caucasians (OR=2.23; 95% CI 1.44-3.46; P=0.0003). However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84-2.59; P=0.18).

Conclusions: In conclusion, this meta-analysis suggests that PAI-1 4G/5G polymorphism might be associated with RPL development in Caucasians.

Show MeSH
Related in: MedlinePlus